Grace Therapeutics, Inc. Common Stock

GRCENASDAQ • USD
1.69 USD
↘ 0.06 (3.43%)🟢LIVE (AS OF 02:22 PM EST)
🟢Market: OPEN

Shares of Grace Therapeutics, Inc. Common Stock (GRCE) are trading at $1.69. Technical and fundamental signals converge bearish — technicals rate "Strong Sell" while fundamentals read "Sell". Key drivers include a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On the valuation side, GRCE appears attractively valued relative to sector peers across key multiples.

Technical & fundamental data as of Nov 16, 2026.

Open?$1.75
High?$1.88
Low?$1.69
Prev. Close?$1.75
Volume?80.9K
Avg. Volume?103.2K
VWAP?$1.74
Rel. Volume?0.78x
Bid / Ask
Bid?$1.47 × 100
Ask?$1.95 × 100
Spread?$0.48
Midpoint?$1.71
Valuation & Ratios
Market Cap?36.8M
Shares Out?N/A
Float?15.1M
Float %?71.6%
P/E Ratio?N/A
P/B Ratio?0.66
EPS?-$1.02
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Grace Therapeutics Inc is a late-stage biopharma company with drug candidates addressing rare and orphan diseases. Its development pipeline consists of the following product candidates: GTx-104, a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage (aSAH); GTx-102, targeted for the treatment of ataxia-telangiectasia (A-T) in a pediatric population; and GTx-101, a topical bio adhesive film-forming bupivacaine spray for Postherpetic Neuralgia (PHN), which can be persistent and often causes debilitating pain following infection by the shingles virus. The company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights.
Employees
5
Market Cap
36.8M
Industry
PHARMACEUTICAL PREPARATIONS
Listed
2011-04-26
Address
103 CARNEGIE CENTER
PRINCETON, NJ 08540
Phone: 609-322-1602
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-3/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
73
Momentum?
50
Short Sent.?
48
Piotroski F-Score?0/9Weak
Altman Z-Score?3.05Safe
Confidence?40%Low
Full Fundamental Analysis →
Short InterestVery High
Short % of Float?11.07%High
Short Interest?1.7M
Days to Cover?12.3
Free Float15.1M
Avg Daily Volume135.2K
Settlement Date2026-10-30
Financial Health
Current Ratio?13.61Strong
Quick Ratio?13.61Strong
Cash Ratio?13.20Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.66CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.5CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
3
-38.6%WEAK▾
ROA?
S&P
3
-37.1%WEAK▾
Cash Flow & Enterprise
FCF?$-8930000
Enterprise Value?$15.5M
Fundamentals ratios updated end of day